Across TCGA pan-cancer cohorts, CPA4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPA4 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CPA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM, BLCA, and LUAD are the cancer types where CPA4 Mutation most reproducibly stratifies survival.